<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715529</url>
  </required_header>
  <id_info>
    <org_study_id>F0025-101</org_study_id>
    <nct_id>NCT04715529</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation and Food Effect Study to Assess the Safety, Tolerance, and Pharmacokinetics of FZJ-003 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and&#xD;
      fasting/postprandial pharmacokinetics of FZJ-003, an oral Janus kinase1 (JAK1) inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SAD and MAD: 6 cohorts, 8 subjects take FZJ-003 and 2 subjects take placebo; Food Effect on Phamocokinetics: 14 subjects, crossover designing</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to 72 hours postdose</time_frame>
    <description>Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; ECG testing). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) parameters of percent and actual change from baseline for a panel of JAK-dependent biomarkers</measure>
    <time_frame>up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>FZJ-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FZJ-003</intervention_name>
    <description>Subjects will receive FZJ-003 oral capsules in a dose escalation format.</description>
    <arm_group_label>FZJ-003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent；&#xD;
&#xD;
          2. Communicate well with the researcher and be able to complete the research in&#xD;
             accordance with the research regulations；&#xD;
&#xD;
          3. No plan for pregnancy in the next 6 months and voluntarily take effective&#xD;
             contraceptive measures; No plan for sperm or egg donation；&#xD;
&#xD;
          4. Healthy male and/or female subjects between the ages of 18 and 50 years ( inclusive)；&#xD;
&#xD;
          5. Male body weight≥50.0kg or female body weight≥45.0kg; Body Mass Index (BMI) between 18&#xD;
             to 28 (both inclusive), calculated as weight in kg / height in m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Someone smoking more than 5 pieces per day within the 3 months before the trial；&#xD;
&#xD;
          2. Suspected of being allergic to investigational drug or any ingredient in the&#xD;
             investigational drug, or people with allergies (multi-drug or food allergies)；&#xD;
&#xD;
          3. Having a history of alcohol abuse (14 units of alcohol per week: 1 units = beer 285&#xD;
             mL, or 25 mL of spirits, or 100 mL of wine);&#xD;
&#xD;
          4. Blood donation or extensive blood loss ≥400 mL within 3 months before screening, or&#xD;
             planning blood donors during the study;&#xD;
&#xD;
          5. Urine drug test positive or have a history of drug abuse or drug use in the past 5&#xD;
             years;&#xD;
&#xD;
          6. Subjects who were intolerant of high-fat meals (2 boiled eggs, 1 slices of buttered&#xD;
             bacon toast, a box of fries, and a glass of whole milk) were applied only to subjects&#xD;
             who participated in the postprandial test;&#xD;
&#xD;
          7. Taked any drug within 14 days before screening, including prescription drugs,&#xD;
             over-the-counter drugs, Chinese herbal medicines and health products (except regular&#xD;
             supplementary vitamins);&#xD;
&#xD;
          8. Taked any drug that changes liver drug enzyme activity within 28 days before&#xD;
             screening, such as CYP3A4 inhibitors or inducers;&#xD;
&#xD;
          9. Major changes in diet or exercise habits within 2 weeks before screening or during the&#xD;
             period from screening to administration;&#xD;
&#xD;
         10. Took a special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous&#xD;
             exercise, and other activities that affect drug absorption, distribution, metabolism,&#xD;
             excretion and so on within 2 weeks before screening;&#xD;
&#xD;
         11. Received or planned to receive any vaccine within 30 days before and after the trial;&#xD;
&#xD;
         12. Participated in clinical trials within 3 months before the first administration of the&#xD;
             study, or planned to participate in other clinical trials during the study period;&#xD;
&#xD;
         13. Having difficulty of swallowing or any history of gastrointestinal diseases that&#xD;
             affect drug absorption;&#xD;
&#xD;
         14. With low immune function or immunodeficiency, or long-term use of immunosuppressive&#xD;
             drugs; or used immunosuppressive drugs within 30 days before screeing;&#xD;
&#xD;
         15. Have or have had malignant tumors；&#xD;
&#xD;
         16. Active tuberculosis; or have a history of tuberculosis or latent tuberculosis&#xD;
             infection; tuberculosis infection T cell spot test positive;&#xD;
&#xD;
         17. Any infection that has been determined to be clinically significant by the&#xD;
             investigator within 3 months or any infection within 7 days before the study;&#xD;
&#xD;
         18. Herpes or varicella within 3 months before the trial;&#xD;
&#xD;
         19. Underwent major trauma or major surgery in 3 months before screening, or have plan for&#xD;
             surgery in trial;&#xD;
&#xD;
         20. Have a history of diverticulitis, peptic ulcer or perforation of digestive tract；&#xD;
&#xD;
         21. Clinical laboratory tests are abnormal and have clinical significance, or other&#xD;
             clinical findings showing clinically significant diseases (including but not limited&#xD;
             to heart Cerebrovascular, gastrointestinal, lungs, endocrine, renal, nerves, blood,&#xD;
             immunizations, or mental disease);&#xD;
&#xD;
         22. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening；or&#xD;
             test positive for human immunodeficiency virus (HIV) at Screening; or syphilis&#xD;
             treponema pallidum antibody and syphilis rapid plasma reagin test are positive;&#xD;
&#xD;
         23. QTcB interval greater than (&gt;) 470 (male) or 480 (female) milliseconds;&#xD;
&#xD;
         24. Female subjects are in lactation or serum pregnancy test are positive during screening&#xD;
             or during the test;&#xD;
&#xD;
         25. Acute illness or combination therapy from the screening stage to administration;&#xD;
&#xD;
         26. Taking chocolate, any caffeine, or xanthine-rich food or drink at least 48 hours prior&#xD;
             to the use of the study drug;&#xD;
&#xD;
         27. Taking any alcoholic products within 24 hours prior to the use of the study drug, or&#xD;
             cannot limit alcohol drinks as required in trial;&#xD;
&#xD;
         28. Other circumstances that is deemed not appropriate for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanhua Ding, MD</last_name>
    <phone>+86-0431-88782705</phone>
    <email>dingyanhua2003@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LiYuan Zhao</last_name>
      <phone>+86 0431-88782013</phone>
      <email>kjkzhaoliyuan@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

